Expert Interview
Discussing with a provider the commercial outlook for Abeona Therapeutics' Zevaskyn and their experience with the first commercially treated patient for RDEB
Ticker(s): ABEO, KRYSInstitution: Stanford University
- Clinical Professor of Dermatology and Pediatrics and Chief of Pediatric Dermatology at the Department of Dermatology at Stanford
- Currently treats 4-6 RDEB patients each month.
- Strong interest and expertise in clinical and translational research especially in the area of rare genetic disorders. Experienced in drug repurposing and trans-epidermal drug delivery and directs multidisciplinary care of patients with complex dermatologic conditions, genetic skin disease and vascular anomalies.
How many RDEB patients do you manage?
Added By: wilson_adminWhat has been your overall experience with Zevaskyn?
Added By: wilson_adminWhat is the outlook for Zevaskyn in your QTC over the next few quarters?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
